184 related articles for article (PubMed ID: 23406047)
1. BRAF V600E inhibition in anaplastic thyroid cancer.
Rosove MH; Peddi PF; Glaspy JA
N Engl J Med; 2013 Feb; 368(7):684-5. PubMed ID: 23406047
[No Abstract] [Full Text] [Related]
2. Sustained Response to Vemurafenib in a BRAF
Prager GW; Koperek O; Mayerhoefer ME; Muellauer L; Wrba F; Niederle B; Zielinski CC; Raderer M
Thyroid; 2016 Oct; 26(10):1515-1516. PubMed ID: 27532222
[No Abstract] [Full Text] [Related]
3. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S
Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
Cancer Discov; 2016 Oct; 6(10):OF4. PubMed ID: 27554612
[TBL] [Abstract][Full Text] [Related]
5. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
6. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
7. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
Husain A; Hu N; Sadow PM; Nucera C
Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
[No Abstract] [Full Text] [Related]
9. BRAF inhibition in refractory hairy-cell leukemia.
Dietrich S; Glimm H; Andrulis M; von Kalle C; Ho AD; Zenz T
N Engl J Med; 2012 May; 366(21):2038-40. PubMed ID: 22621641
[No Abstract] [Full Text] [Related]
10. Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.
Kim SH; Shin HY; Kim YS; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2014 Sep; 34(9):4857-68. PubMed ID: 25202067
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
Takano T; Ito Y; Hirokawa M; Yoshida H; Miyauchi A
Br J Cancer; 2007 May; 96(10):1549-53. PubMed ID: 17453004
[TBL] [Abstract][Full Text] [Related]
12. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.
Nehs MA; Nagarkatti S; Nucera C; Hodin RA; Parangi S
Surgery; 2010 Dec; 148(6):1154-62; discussion 1162. PubMed ID: 21134546
[TBL] [Abstract][Full Text] [Related]
13. Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.
Kent J; Erwin P; Haraf D; Liao CY; Durham J; Angelos P; Agrawal N; Baird BJ; Madariaga MLL
Ann Thorac Surg; 2023 May; 115(5):e117-e120. PubMed ID: 35504360
[TBL] [Abstract][Full Text] [Related]
14. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.
Vanden Borre P; Gunda V; McFadden DG; Sadow PM; Varmeh S; Bernasconi M; Parangi S
Oncotarget; 2014 Jun; 5(12):3996-4010. PubMed ID: 24994118
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer: Targeting BRAF mutations equally?
Hutchinson L
Nat Rev Clin Oncol; 2016 Jan; 13(1):4. PubMed ID: 26552951
[No Abstract] [Full Text] [Related]
16. Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma.
Rushton S; Burghel G; Wallace A; Nonaka D
Histopathology; 2016 Sep; 69(3):524-6. PubMed ID: 26987976
[No Abstract] [Full Text] [Related]
17. Pilomyxoid astrocytoma treated successfully with vemurafenib.
Skrypek M; Foreman N; Guillaume D; Moertel C
Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
[TBL] [Abstract][Full Text] [Related]
18. [Progress of anti-tumor study based on BRAF].
Yan GR; Xu ZJ; Wang HY; Zhu WL
Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
[TBL] [Abstract][Full Text] [Related]
19. Resistance to BRAF inhibition in melanomas.
Solit DB; Rosen N
N Engl J Med; 2011 Feb; 364(8):772-4. PubMed ID: 21345109
[No Abstract] [Full Text] [Related]
20. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
